2026 Global: Infectious Respiratory Disease Diagnostics Market-Competitive Review (2032) report
Description
The 2026 Global: Infectious Respiratory Disease Diagnostics Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Roche Diagnostics, Basel, Switzerland, is a leading force in infectious respiratory disease testing, offering PCR platforms, rapid antigen assays, and integrated workflows for hospitals and central laboratories. Abbott, headquartered in Abbott Park, Illinois, United States, combines molecular and immunoassay capabilities with point‑of‑care solutions to support frontline testing during seasonal outbreaks and pandemics. Thermo Fisher Scientific, based in Waltham, Massachusetts, United States, provides high‑throughput real‑time PCR systems, reagents, and multiplex panels that enable large‑scale respiratory surveillance and rapid confirmatory testing. Danaher, headquartered in Washington, D.C., United States, advances molecular diagnostics through Cepheid and related brands, delivering cartridge‑based tests and automation that accelerate pathogen detection and workflow efficiency in diverse settings. These firms collectively drive assay development, automation, and distributed testing networks that underpin rapid response to influenza, RSV, SARS‑CoV‑2, and emergent respiratory pathogens. This market concentration supports innovation in multiplex assays and sample‑to‑answer platforms. Hospitals, reference labs, and clinics benefit widely.
Qiagen, headquartered in Hilden, Germany, supplies robust molecular kits, automation platforms, and digital analytics that enable fast, scalable respiratory pathogen testing in core laboratories and decentralized clinics. BioMérieux, based in Marcy‑l'Étoile, France, delivers integrated diagnostic solutions spanning nucleic acid amplification, immunoassays, and rapid point‑of‑care formats for influenza, RSV, SARS‑CoV‑2, and related pathogens. BD, headquartered in Franklin Lakes, New Jersey, United States, focuses on pre‑analytical workflows, solid‑tissue and liquid sampling, and instrument platforms that support high‑throughput respiratory testing in hospital networks and central reference labs. Hologic, headquartered in Marlborough, Massachusetts, United States, expands access to respiratory diagnostics with automated molecular systems and syndromic panels that combine imaging, molecular, and nonmolecular assays to inform clinical decisions. These players collectively drive multiplex testing, global distribution, and data integration for surveillance and patient management across respiratory illnesses. Public health laboratories, hospitals, and biopharma collaborators benefit from standardized workflows and validated assay options. Globally today.
DiaSorin, headquartered in Saluggia, Italy, specializes in serology and molecular diagnostics for infectious diseases and respiratory pathogens, offering the LIAISON immunoassays and real‑time PCR platforms that support screening of influenza, RSV, and SARS‑CoV‑2 in hospital and reference settings. Grifols, headquartered in Barcelona, Spain, combines transfusion medicine expertise with diagnostic analytics, delivering immunoassay panels, molecular assays, and point‑of‑care testing that support surveillance, triage, and patient management during respiratory disease outbreaks. These companies broaden global access to validated assays and integrated workflows, complementing larger platforms and catering to markets with varying laboratory capacities. By fostering collaborations with public health agencies, they enable data sharing, standardization, and rapid deployment of testing during seasonal peaks and emerging outbreaks. From centralized reference laboratories to rural clinics, the infectious respiratory disease diagnostics market relies on diverse capabilities, competitive pricing, and robust quality systems to protect populations and curb transmission. Continued investment will broaden access globally soon.
Roche Diagnostics, Basel, Switzerland, is a leading force in infectious respiratory disease testing, offering PCR platforms, rapid antigen assays, and integrated workflows for hospitals and central laboratories. Abbott, headquartered in Abbott Park, Illinois, United States, combines molecular and immunoassay capabilities with point‑of‑care solutions to support frontline testing during seasonal outbreaks and pandemics. Thermo Fisher Scientific, based in Waltham, Massachusetts, United States, provides high‑throughput real‑time PCR systems, reagents, and multiplex panels that enable large‑scale respiratory surveillance and rapid confirmatory testing. Danaher, headquartered in Washington, D.C., United States, advances molecular diagnostics through Cepheid and related brands, delivering cartridge‑based tests and automation that accelerate pathogen detection and workflow efficiency in diverse settings. These firms collectively drive assay development, automation, and distributed testing networks that underpin rapid response to influenza, RSV, SARS‑CoV‑2, and emergent respiratory pathogens. This market concentration supports innovation in multiplex assays and sample‑to‑answer platforms. Hospitals, reference labs, and clinics benefit widely.
Qiagen, headquartered in Hilden, Germany, supplies robust molecular kits, automation platforms, and digital analytics that enable fast, scalable respiratory pathogen testing in core laboratories and decentralized clinics. BioMérieux, based in Marcy‑l'Étoile, France, delivers integrated diagnostic solutions spanning nucleic acid amplification, immunoassays, and rapid point‑of‑care formats for influenza, RSV, SARS‑CoV‑2, and related pathogens. BD, headquartered in Franklin Lakes, New Jersey, United States, focuses on pre‑analytical workflows, solid‑tissue and liquid sampling, and instrument platforms that support high‑throughput respiratory testing in hospital networks and central reference labs. Hologic, headquartered in Marlborough, Massachusetts, United States, expands access to respiratory diagnostics with automated molecular systems and syndromic panels that combine imaging, molecular, and nonmolecular assays to inform clinical decisions. These players collectively drive multiplex testing, global distribution, and data integration for surveillance and patient management across respiratory illnesses. Public health laboratories, hospitals, and biopharma collaborators benefit from standardized workflows and validated assay options. Globally today.
DiaSorin, headquartered in Saluggia, Italy, specializes in serology and molecular diagnostics for infectious diseases and respiratory pathogens, offering the LIAISON immunoassays and real‑time PCR platforms that support screening of influenza, RSV, and SARS‑CoV‑2 in hospital and reference settings. Grifols, headquartered in Barcelona, Spain, combines transfusion medicine expertise with diagnostic analytics, delivering immunoassay panels, molecular assays, and point‑of‑care testing that support surveillance, triage, and patient management during respiratory disease outbreaks. These companies broaden global access to validated assays and integrated workflows, complementing larger platforms and catering to markets with varying laboratory capacities. By fostering collaborations with public health agencies, they enable data sharing, standardization, and rapid deployment of testing during seasonal peaks and emerging outbreaks. From centralized reference laboratories to rural clinics, the infectious respiratory disease diagnostics market relies on diverse capabilities, competitive pricing, and robust quality systems to protect populations and curb transmission. Continued investment will broaden access globally soon.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
